Dewpoint is the first company to apply this emerging understanding of biomolecular condensates to advance a revolutionary approach to drug discovery. We believe that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates — including cancer, neurodegeneration, cardiopulmonary and metabolic diseases.

The discovery of biomolecular condensates, for which our co-founder Tony Hyman was awarded the 2023 Breakthrough Prize in Life Sciences,  led to an entirely new understanding of biology and has transformed the way we think about the origin and treatment of diseases.

We are advancing these learnings to identify new targets and mechanisms of action across multiple biological pathways to develop therapies for difficult-to-treat diseases. Our research has the potential to be the next great leap in drug discovery and make a real impact on patients’ lives.

At Dewpoint, we’re not only leading a revolution in drug discovery, we’re re-defining the very spirit of what company culture can be. Together we’ve built a unique place to work. Our teams feel inspired, valued and included, and Dewpoint is a place where you can show up as your authentic self to impact science, patients and the future of medicine.

For every role, we hire based on talent, aptitude and an eagerness to learn and grow. 

We have the experience to help the right person further develop capabilities and thrive to their full potential.

So if you don’t see a perfect opportunity, but you’re still interested in being part of the D.team, please get in touch.